| 干性年龄相关性黄斑变性现代医药与中医药研究新进展 |
| |
| 引用本文： | 邢露,贾礼伊,孙晓莹,郭蒙,靳洁,王引弟,黄领,李奕衡,何钟竞,李蓉,曹慧玲.干性年龄相关性黄斑变性现代医药与中医药研究新进展[J].国际眼科杂志,2022,22(5):803-808. |
| |
| 作者姓名： | 邢露 贾礼伊 孙晓莹 郭蒙 靳洁 王引弟 黄领 李奕衡 何钟竞 李蓉 曹慧玲 |
| |
| 作者单位： | 中国陕西省西安市,陕西省缺血性心血管疾病重点实验室 西安市心血管代谢疾病基础与转化重点实验室 西安医学院基础与转化医学研究所,中国陕西省咸阳市,陕西中医药大学药学院,中国陕西省咸阳市,陕西中医药大学药学院,中国陕西省咸阳市,陕西中医药大学药学院,中国陕西省咸阳市,陕西中医药大学药学院,中国陕西省咸阳市,陕西中医药大学药学院,中国陕西省咸阳市,陕西中医药大学药学院,中国陕西省西安市,西北大学生命科学学院,中国陕西省西安市,西北大学生命科学学院,中国陕西省西安市,西安医学院第一附属医院眼科,中国陕西省西安市,陕西省缺血性心血管疾病重点实验室 西安市心血管代谢疾病基础与转化重点实验室 西安医学院基础与转化医学研究所; 中国陕西省咸阳市,陕西中医药大学药学院; 中国陕西省西安市,西北大学生命科学学院 |
| |
| 基金项目： | 陕西省教育厅2019年度重点科学研究计划项目(No.19JS058); 国家自然科学基金项目(No.U1932130); 陕西省科技厅2021年度自然科学青年基金项目(No.2021JQ-788); 西安医学院博士基金项目(No.2018DOC10) |
| |
| 摘 要： | 年龄相关性黄斑变性(ARMD)是中老年人不可逆性视力损害的一种主要原因，严重影响个人生活质量并加重社会卫生经济负担。晚期ARMD在临床上有两种表现类型，即干性ARMD(dARMD)和湿性ARMD(nARMD)。nARMD以抗血管内皮生长因子作为一线药物已取得显著疗效，而dARMD尚无确切的治疗方法。本文就dARMD在临床试验中取得显著进展、可望上市的潜在药物、生物疗法和中医中药进行综述，包括抗炎药(强力霉素和FHTR2163)、抗氧化药(利舒尼布和依来米普瑞肽)、补体抑制剂(APL-2和滋目若)、视觉周期调节剂(ALK-001)、神经保护剂(溴莫尼定)、干细胞移植(MA09-hRPE和BMMF)、基因疗法(HMR59)和中医中药(藏红花、姜黄素、槲皮素和白藜芦醇)等。这些药物临床试验疗效显著，应用前景广阔，为ARMD改善与治疗带来巨大希望。
|
| 关 键 词： | 年龄相关性黄斑变性 干性 地图状萎缩 玻璃膜疣 新药 补体抑制剂 干细胞移植 中药 |
| 收稿时间： | 2022/2/10 0:00:00 |
| 修稿时间： | 2022/3/29 0:00:00 |
Research advances of modern and traditional medicine on dry age-related macular degeneration |
| |
| Lu Xing,Li-Yi Ji,Xiao-Ying Sun,Meng Guo,Jie Jin,Yin-Di Wang,Ling Huang,Yi-Heng Li,Zhong-Jing He,Rong Li and Hui-Ling Cao.Research advances of modern and traditional medicine on dry age-related macular degeneration[J].International Journal of Ophthalmology,2022,22(5):803-808. |
| |
| Authors: | Lu Xing Li-Yi Ji Xiao-Ying Sun Meng Guo Jie Jin Yin-Di Wang Ling Huang Yi-Heng Li Zhong-Jing He Rong Li and Hui-Ling Cao |
| |
| Institution: | Shaanxi Key Laboratory of Ischemic Cardiovascular Disease;Xi''an Key Laboratory of Basic and Translation of Cardiovascular Diabetic Disease;Institute of Basic and Translational Medicine, Xi''an Medical University, Xi''an 710021, Shaanxi Province, China,School of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, Shaanxi Province, China,School of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, Shaanxi Province, China,School of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, Shaanxi Province, China,School of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, Shaanxi Province, China,School of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, Shaanxi Province, China,School of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, Shaanxi Province, China,School of Life Sciences, Northwest University, Xi''an 710069, Shaanxi Province, China,School of Life Sciences, Northwest University, Xi''an 710069, Shaanxi Province, China,Department of Ophthalmology, the First Affiliated Hospital of Xi''an Medical University, Xi''an 710077, Shaanxi Province, China and Shaanxi Key Laboratory of Ischemic Cardiovascular Disease;Xi''an Key Laboratory of Basic and Translation of Cardiovascular Diabetic Disease;Institute of Basic and Translational Medicine, Xi''an Medical University, Xi''an 710021, Shaanxi Province, China; School of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, Shaanxi Province, China; School of Life Sciences, Northwest University, Xi''an 710069, Shaanxi Province, China |
| |
| Abstract: | Age-related macular degeneration(ARMD)is one of the main causes of irreversible visual impairment in the middle-aged and elderly people, which severely impacts the patient''s life quality and poses a substantial health economic burden on society. There are two types of late ARMD in clinic: wet ARMD and dry ARMD. Anti-vascular endothelial growth factor drugs, as first-line clinical drugs for wet ARMD, achieved remarkable efficacy. For dry ARMD, however, effective therapies are in the air. This review focuses on the potential drugs, biological therapies and traditional Chinese medicines that made significant progresses in clinical trials for dry ARMD, including anti-inflammatory drugs(doxycycline and FHTR2163), anti-oxidants(risuteganib and elamipretide), complement inhibitors(APL-2 and zimura), visual cycle modulators(ALK-001), neuroprotective agents(brimonidine), stem cell transplantation(MA09-hRPE and BMMF), gene therapy(HMR59), and traditional Chinese medicine(saffron, curcumin, quercetin and resveratrol). The new drugs exhibited favorable clinical efficacy and broad application prospects, which would foster hope for improvement and treatment of ARMD. |
| |
| Keywords: | age-related macular degeneration dry geographic atrophy drusen new drugs complement inhibitor stem cell transplantation traditional Chinese medicine |
|
| 点击此处可从《国际眼科杂志》浏览原始摘要信息 |
| 点击此处可从《国际眼科杂志》下载免费的PDF全文 |
|
